DK1603598T3 - Radiomærkede konjugater baseret på substans P og anvendelser heraf - Google Patents

Radiomærkede konjugater baseret på substans P og anvendelser heraf

Info

Publication number
DK1603598T3
DK1603598T3 DK04721547T DK04721547T DK1603598T3 DK 1603598 T3 DK1603598 T3 DK 1603598T3 DK 04721547 T DK04721547 T DK 04721547T DK 04721547 T DK04721547 T DK 04721547T DK 1603598 T3 DK1603598 T3 DK 1603598T3
Authority
DK
Denmark
Prior art keywords
substance
dodecane
applications
conjugates based
tetraazacyclo
Prior art date
Application number
DK04721547T
Other languages
English (en)
Inventor
Adrian Merlo
Helmut Maecke
Jean-Claude Reubi
Stephan Good
Original Assignee
Univ Bern
Universitaetsspital Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bern, Universitaetsspital Basel filed Critical Univ Bern
Application granted granted Critical
Publication of DK1603598T3 publication Critical patent/DK1603598T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK04721547T 2003-03-19 2004-03-18 Radiomærkede konjugater baseret på substans P og anvendelser heraf DK1603598T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03006061 2003-03-19
PCT/EP2004/050329 WO2004082722A2 (en) 2003-03-19 2004-03-18 Radiolabeled conjugates based on substance p and the uses thereof

Publications (1)

Publication Number Publication Date
DK1603598T3 true DK1603598T3 (da) 2009-01-26

Family

ID=33016829

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04721547T DK1603598T3 (da) 2003-03-19 2004-03-18 Radiomærkede konjugater baseret på substans P og anvendelser heraf

Country Status (13)

Country Link
US (1) US20070053837A1 (da)
EP (1) EP1603598B1 (da)
JP (1) JP2007527366A (da)
AT (1) ATE410191T1 (da)
AU (1) AU2004222531A1 (da)
CA (1) CA2519315A1 (da)
DE (1) DE602004016968D1 (da)
DK (1) DK1603598T3 (da)
ES (1) ES2312983T3 (da)
HK (1) HK1081884A1 (da)
NZ (1) NZ542371A (da)
SI (1) SI1603598T1 (da)
WO (1) WO2004082722A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
CN101631801B (zh) 2006-10-16 2013-06-05 索尔克生物学研究院 受体（sstr2）-选择性生长抑素拮抗剂
GB0624587D0 (en) * 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
CA2758049A1 (en) * 2009-03-30 2010-10-14 E.I. Du Pont De Nemours And Company Peptide-based systems for delivery of cosmetic agents
US11141494B2 (en) 2014-08-09 2021-10-12 Purdue Research Foundation Development of neurokinin-1 receptor-binding agent delivery conjugates
AU2017217271C1 (en) 2016-02-09 2021-08-05 Cdrd Ventures Inc. Somatostatin receptor antagonist compounds and methods of using the same
WO2018119313A1 (en) * 2016-12-23 2018-06-28 The Johns Hopkins University Tumor and immune cell imaging based on pd-l1 expression
GB201705258D0 (en) * 2017-03-31 2017-05-17 South African Nuclear Energy Corp Ltd Imaging agent
JP2020518673A (ja) 2017-05-05 2020-06-25 フュージョン・ファーマシューティカルズ・インコーポレイテッド 二官能性キレートの薬物動態増強及びその使用
IL313115A (en) 2017-05-05 2024-07-01 Centre For Probe Dev And Commercialization R1–IGF monoclonal antibodies and their use
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
AU2020237477B2 (en) * 2019-03-11 2023-03-16 Biocompatibles Uk Limited Radioactive microshperes for the treatment of CNS tumours

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750646A (en) * 1987-09-24 1998-05-12 The Administrators Of The Tulane Educational Fund Bradykinin analogs with non-peptide bond
AU6718900A (en) * 1999-07-05 2001-01-22 Pedro Ortiz Armua A radiolabeled mammalian tachykinin peptide analogue
AU2001277488B2 (en) * 2000-05-12 2006-05-18 University Hospital Prochelators of radiometal labeled molecules
EP1283216A1 (en) * 2001-08-10 2003-02-12 Mallinckrodt Inc. Somatostatin analogues binding to all somatostatin receptor subtypes and their use
PL377591A1 (pl) * 2002-10-02 2006-02-06 Zealand Pharma A/S Stabilizowane związki eksendyny-4

Also Published As

Publication number Publication date
WO2004082722A3 (en) 2005-01-06
JP2007527366A (ja) 2007-09-27
DE602004016968D1 (de) 2008-11-20
CA2519315A1 (en) 2004-09-30
HK1081884A1 (en) 2006-05-26
EP1603598B1 (en) 2008-10-08
AU2004222531A1 (en) 2004-09-30
WO2004082722A2 (en) 2004-09-30
ES2312983T3 (es) 2009-03-01
SI1603598T1 (sl) 2009-02-28
EP1603598A2 (en) 2005-12-14
US20070053837A1 (en) 2007-03-08
NZ542371A (en) 2008-10-31
ATE410191T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
HK1081884A1 (en) Radiolabeled conjugates based on substance p and the uses thereof
YU61701A (sh) Postupak i kit za efikasno radioobeležavanje proteina sa terapeutskim radioizotopom
NO20031407L (no) Glukopyranosyloksybenzylbenzen-derivater og medisinske sammensetninger inneholdende det samme
DK1472541T3 (da) Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
EP2281580A3 (en) Labeled gastrin releasing peptides (GRP)
NO20042873L (no) Ladnings- eller partikkelavfoling
ATE477224T1 (de) Verwendung von miniatursierten vorrichtungen zur herstellung von radiomarkierten verbindungen
NO20034020L (no) Nye MHC molekylforbindelser, og metoder for anvendelse av disse forbindelsene for diagnose og terapi, og anvendelse av MHC molekyler
CY1110923T1 (el) Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων
ES2114209T3 (es) Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s.
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
EA200601524A1 (ru) Альфа-излучающие частицы гидроксиапатита
DE60206272D1 (de) Chelatorkonjugate mit verbesserten eigenschaften
ATE178053T1 (de) N2s2-chelatoren des hydrazino-typs
DE60312136D1 (de) Radiofluorierungsverfahren
NO20010487D0 (no) Disubstituert maleimidforbindelse og farmasöytisk anvendelse herav
WO2005053752A3 (en) Novel imaging agents comprising caspase-3 inhibitors
ITMI20011708A0 (it) Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
NO20005164D0 (no) 2-metylpropionsyre-derivater og medisinske sammensetninger inneholdende det samme
MA24854A1 (fr) Inhibiteurs d'oxyde nitrique synthase
AU7548901A (en) Liposomal encapsulation of chelated actinium-225 and uses thereof
ID28035A (id) Kegunaan turunan antrasiklin untuk pengobatan tumor hati
교회는 et al. Cogyright (C) 2003 NuriMedia Co․, Ltd.
NO20015207L (no) Anvendelse av antiprogestagener i kombinert terapi
ITMC20050119A1 (it) SINTESI CHIMICA DI (RAMEDEOSSIGLUCOSIO;[64Cu] TETA-DEOSSIGLUCOSIO), E UTILIZZO DELLO STESSO COME AGENTE PER INDAGINI PET (POSITRON EMISSION TOMOGRAPHY IMAGING) E PER LA RADIOTERAPIA.